Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)

Mark M. Awad, Giulia Costanza Leonardi, Sasha Kravets, Suzanne Eleanor Dahlberg, Alexander E. Drilon, Sinead Noonan, D. Ross Camidge, Sai-Hong Ignatius Ou, Daniel Botelho Costa, Shirish M. Gadgeel, Conor Ernst Steuer, Patrick M. Forde, Viola Weijia Zhu, Yoko Korenaga Fukuda, Jeffrey W. Clark, Pasi A. Janne, Tony Mok, Lynette M. Sholl, Rebecca Suk Heist

Dana-Farber Cancer Institute, Boston, MA
Memorial Sloan-Kettering Cancer Center, New York, NY
University of Colorado, Aurora, CO
University of Colorado-Denver, Aurora, CO
University of California Irvine Chao Family Comprehensive Cancer Center, Orange, CA
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Karmanos Cancer Institute, Detroit, MI
Winship Cancer Institute, Atlanta, GA
Johns Hopkins Kimmel Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, MD
University of California San Francisco, Fresno, CA
Frisbie Memorial Hospital, Rochester, NH
Massachusetts General Hospital Cancer Center, Boston, MA
Chinese University of Hong Kong, Hong Kong, China
Brigham and Women‘s Hospital, Boston, MA
Massachusetts General Hospital for Children Cancer Center, Boston, MA